Browse the evidence

Ultrasonography is a reliable and affordable tool for measuring fat and muscle mass.

Practitioners can consider ultrasonography for better assessment of body composition in patients.

As muscle mass decreases, the risk of conditions like type 2 diabetes rises.

Addressing muscle mass in obesity management could improve health outcomes.

The current Russian clinical guidelines for the treatment of obesity include drugs such as orlistat, sibutramine, and liraglutide.

Clinicians should be aware of the current guidelines when prescribing treatments for obesity.

There is a need to expand existing clinical recommendations for the treatment of patients with obesity.

Healthcare providers should consider integrating new pharmacotherapies into their treatment plans for obesity.

MR-O and Conv-O similarly increased fecal fat percentage from 3.8% to 13.5%, confirming pharmacodynamic equivalence.

Both formulations can be considered equally effective in increasing fecal fat excretion.

The new weight loss product MR-OA retains the dietary energy loss pathway used in Conv-O.

MR-OA can be expected to function similarly to Conv-O in promoting fat loss.

Psychological capabilities and reflective motivation have direct effects on the frequency of resistance training participation among GLP-1 medication users.

Practitioners should focus on enhancing psychological capabilities and motivation to improve resistance training frequency in GLP-1 users.

Psychological capabilities directly or indirectly influence all resistance training participation characteristics among GLP-1 medication users.

Enhancing psychological capabilities is crucial for improving overall resistance training participation.

Co-stimulation of GLP-1 with other receptors provides additional therapeutic benefits.

Combining GLP-1 therapy with other hormonal treatments may enhance effectiveness.

Obesity-related hypertension is a significant contributor to cardiovascular morbidity and mortality.

Healthcare providers should prioritize addressing obesity to mitigate hypertension and related cardiovascular risks.

Behavioral support is necessary to maximize the benefits of incretin therapy.

Practitioners should integrate behavioral support strategies into incretin therapy plans.

Recent studies highlight the efficacy of diabetic agents and other novel therapies in shaping obesity-associated hypertension management guidelines.

Healthcare providers should consider incorporating diabetic agents and novel therapies into treatment plans.

Both 0839 and 0833 improved metabolic parameters and reduced body weight primarily by fat mass reduction.

These compounds may be effective for fat loss and improving metabolic health.

Übergewicht erhöht die Häufigkeit von Beckenbodenfunktionsstörungen, wobei ein höherer BMI mit einer höheren Prävalenz von Harn- und Stuhlinkontinenz sowie Genitaldeszensus korreliert.

Praktiker sollten Übergewicht als Risikofaktor für Beckenbodenfunktionsstörungen bei Frauen berücksichtigen.

Bei Schwangeren kann Übergewicht das Risiko für postpartale Beckenbodenstörungen deutlich erhöhen.

Praktiker sollten prä- und postpartale Maßnahmen zur Beckenbodengesundheit bei übergewichtigen Schwangeren priorisieren.

Tirzepatide demonstrated a positive impact on the cardiovascular system.

Tirzepatide may be beneficial for patients with cardiovascular concerns related to diabetes.

GLP-1 receptor agonists (GLP-1RA) significantly reduce major adverse cardiovascular events (MACE) with a pooled hazard ratio of 0.86.

GLP-1RA can be recommended for reducing cardiovascular risks in patients with type 2 diabetes and obesity.

Both systolic blood pressure (SBP) and weight reductions are independently associated with reduced MACE risk.

Weight management and blood pressure control should be emphasized in treatment plans for these patients.

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in obesity management is increasing.

Practitioners should be aware of the growing role of GLP-1 RAs in obesity treatment.

Endobariatrics (EBT) offers durable weight loss with low complication rates.

EBT can be considered a viable option for patients seeking weight loss with minimal risks.

The combination of an amylin analog and other anti-obesity peptide drugs has demonstrated higher clinical efficacy in reducing body weight than monotherapy.

Combination therapies may be more effective for weight loss than single-drug treatments.

Obesity is associated with many health risks, including hypertension, hyperlipidemia, T2D, CHD, stroke, gallbladder disease, osteoarthritis, sleep apnea, respiratory problems, and some cancers.

Healthcare practitioners should be aware of the extensive health risks associated with obesity.

Up to 40% of weight loss following treatment with GLP-1RA is accounted for by lean mass.

Clinicians should be aware of potential lean mass loss when prescribing GLP-1RA therapies.

Early change in eating-related self-regulation is a stronger predictor of longer-term change in eating-related self-efficacy than the reverse.

Focusing on enhancing self-regulation may be crucial for improving self-efficacy in obesity treatment.